Kim Dong-In, Lee Seo Jin, Park Soonju, Kim Paul, Lee Sun Min, Lee Nakyung, Shum David, Kim Dong Ho, Kim Eui Ho
Viral Immunology Laboratory, Institut Pasteur Korea, Seongnam 13488, Korea.
Department of Pediatrics, Korea Cancer Center Hospital, Seoul 01812, Korea.
Vaccines (Basel). 2022 Nov 4;10(11):1864. doi: 10.3390/vaccines10111864.
During the COVID-19 pandemic, vaccines were developed based on various platform technologies and were approved for emergency use. However, the comparative analysis of immunogenicity and durability of vaccine-induced antibody responses depending on vaccine platforms or vaccination regimens has not been thoroughly examined for mRNA- or viral vector-based vaccines. In this study, we assessed spike-binding IgG levels and neutralizing capacity in 66 vaccinated individuals prime-boost immunized either by homologous (BNT162b2-BNT162b2 or ChAdOx1-ChAdOx1) or heterologous (ChAdOx1-BNT162b2) vaccination for six months after the first vaccination. Despite the discrepancy in intervals for the prime-boost vaccination regimen of different COVID-19 vaccines, we found stronger induction and relatively rapid waning of antibody responses by homologous vaccination of the mRNA vaccine, while weaker boost effect and stable maintenance of humoral immune responses were observed in the viral vector vaccine group over 6 months. Heterologous vaccination with ChAdOx1 and BNT162b2 resulted in an effective boost effect with the highest remaining antibody responses at six months post-primary vaccination.
在新冠疫情期间，基于多种平台技术研发了疫苗并获批紧急使用。然而，对于基于mRNA或病毒载体的疫苗，尚未对取决于疫苗平台或接种方案的疫苗诱导抗体反应的免疫原性和持久性进行全面的比较分析。在本研究中，我们评估了66名接种疫苗个体在首次接种后六个月内通过同源（BNT162b2-BNT162b2或ChAdOx1-ChAdOx1）或异源（ChAdOx1-BNT162b2）接种进行初免-加强免疫后的刺突结合IgG水平和中和能力。尽管不同新冠疫苗的初免-加强接种方案间隔存在差异，但我们发现mRNA疫苗同源接种诱导的抗体反应更强且消退相对较快，而病毒载体疫苗组在6个月内观察到较弱的加强效果和体液免疫反应的稳定维持。ChAdOx1和BNT162b2的异源接种在初次接种后六个月产生了有效的加强效果，剩余抗体反应最高。
